Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease - Immortal time bias in observational studies

被引:196
作者
Suissa, S
机构
[1] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada
[2] McGill Univ, Dept Epidemiol, Montreal, PQ, Canada
[3] McGill Univ, Dept Biostat, Montreal, PQ, Canada
[4] McGill Univ, Dept Med, Montreal, PQ, Canada
关键词
epidemiologic methods; cohort studies; databases; treatment effectiveness; epidemiologic biases;
D O I
10.1164/rccm.200210-1231OC
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Recent large-scale cohort studies that reported an important reduction in mortality and chronic obstructive pulmonary disease (COPD) morbidity with inhaled corticosteroids may be biased. We used a population-based cohort of Saskatchewan residents 55 years of age or over, first hospitalized for COPD during 1990 to 1997, to study this potential bias. These 979 subjects were followed for a year from discharge until their first readmission for COPD or death (389 subjects). Inhaled corticosteroid exposure was measured as any dispensing within 90 days after discharge. Cox's proportional hazards model was used to compare the time-fixed analysis employed in the recent studies with the alternative time-dependent analysis. The time-fixed adjusted rate ratio was 0.69 (95% Cl: 0.55-0.86) for inhaled corticosteroid use within 90 days, whereas the time-dependent rate ratio was 1.00 (95% Cl: 0.79-1.26). With the time-fixed analysis, the rate ratios were affected by the length of the exposure period, decreasing from 0.98 for a 15-day exposure period to 0.51 for 365 days, but remained stable between 1.06 and 0.94 with the time-dependent analysis. Inhaled corticosteroid use after hospitalization for COPD was not found to reduce mortality and morbidity. Although observational studies can be valuable, the recent reports of reductions in mortality and morbidity with inhaled corticosteroids are biased by their inappropriate allocation of exposure and analysis of immortal time.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 21 条
[1]   The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials [J].
Alsaeedi, A ;
Sin, DD ;
McAlister, FA .
AMERICAN JOURNAL OF MEDICINE, 2002, 113 (01) :59-65
[2]  
Altose MD, 2000, NEW ENGL J MED, V343, P1902
[3]  
Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342
[4]   Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease [J].
Bourbeau, J ;
Rouleau, MY ;
Boucher, S .
THORAX, 1998, 53 (06) :477-482
[5]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[6]  
Calverley PMA, 2000, AM J RESP CRIT CARE, V161, P341
[7]  
Downey W, 2000, PHARMACOEPIDEMIOLOGY, V3rd, P325
[8]  
Hurd S, 2000, CHEST, V117, P1
[9]   Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease [J].
Paggiaro, PL ;
Dahle, R ;
Bakran, I ;
Frith, L ;
Hollingworth, K ;
Efthimiou, J .
LANCET, 1998, 351 (9105) :773-780
[10]   Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking [J].
Pauwels, RA ;
Löfdahl, CG ;
Laitinen, LA ;
Schouten, JP ;
Postma, DS ;
Pride, NB ;
Ohlsson, SV .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (25) :1948-1953